/XCUR
XCUR Stock - Exicure, Inc.
Healthcare|BiotechnologyNASDAQ
$5.92-2.79%
$0.17 (-2.79%) • Dec 19
55
GoAI Score
GoAI Score
Weighted average: Momentum (25%) + Sentiment (35%) + Risk (20%) + Value (20%). ≥70 = BUY, ≤35 = SELL.HOLD
Medium Confidence
Momentum
Momentum Score
Based on price vs 50-day MA (40%), 200-day MA (40%), and MA crossover (20%). Higher = stronger uptrend.40
Sentiment
Sentiment Score
Based on analyst price target upside. 50 = neutral, 100 = very bullish (25%+ upside expected).100
Risk Score
Risk Score
Based on stock beta (volatility). Higher score = lower risk. Red (<40) = high volatility, Green (>60) = stable.0
Price Target
Price Target
Average analyst price target from the last quarter. Shows expected upside/downside from current price.+102.7%upside
Target: $12.00
AI Analysis PreviewPremium
Real-time AI-powered market analysis
Precise entry/exit price targets
Risk assessment & position sizing
Unlock GoAI Insights for XCUR
Get institutional-grade AI analysis, real-time signals, and deep market intelligence powered by advanced machine learning.
Buy/Sell Signals
94% win rate on Alpha signals
Deep Analysis
Institutional-grade thesis
Real-Time Alerts
SMS & push notifications
Risk Scoring
Multi-factor analysis
Free 14-day trial • No credit card required
Active Trade Setup
ENTRY ZONE$5.86 – $5.98
TARGET (TP)$12.00
STOP LOSS$5.45
RISK/REWARD1:12.9
Premium members get real-time SMS alerts
Price Chart
Financial Statements
Revenue & Profitability Trend
← Swipe to see more →
Revenue
Net Income (Profit)
Net Loss
Key Metrics
Market CapN/A
P/E RatioN/A
Beta4.08
52W High$22.99
52W Low$3.10
Avg VolumeN/A
Income Statement (Fiscal Year)
| Metric | FY2024 | FY2023 | FY2022 | FY2021 | FY2020 |
|---|---|---|---|---|---|
| Revenue | $500,000 | N/A | $28.83M | $-483,000 | $16.61M |
| Gross Profit | $500,000 | $-1,423,000 | $26.97M | $-483,000 | $-15,481,000 |
| Gross Margin | 100.0% | N/A | 93.6% | 100.0% | -93.2% |
| Operating Income | $-12,232,000 | $-14,996,000 | $-1,831,000 | $-62,549,000 | $-25,436,000 |
| Net Income | $-9,701,000 | $-16,914,000 | $-2,582,000 | $-64,102,000 | $-24,668,000 |
| Net Margin | -1940.2% | N/A | -9.0% | 13271.6% | -148.5% |
| EPS | $-1.59 | $-2.11 | $-0.56 | $-21.70 | $-8.49 |
Company Overview
Exicure, Inc., a biotechnology company, develops therapies for neurological disorders and hair loss based on its proprietary spherical nucleic acid (SNA) technology. Its lead program candidate includes SCN9A that is in preclinical studies for neuropathic and chronic pain. The company has a collaboration, option, and license agreement with AbbVie Inc. to develop SNA-based treatments for hair loss disorders; and collaboration agreement with Ipsen S.A. to research, develop, and commercialize novel spherical nucleic acids for Huntington's disease and Angelman syndrome. Exicure, Inc. was founded in 2011 and is headquartered in Chicago, Illinois.
Visit WebsiteLoading analyst ratings...
Earnings History & Surprises
XCURBeat Rate
25%
Last 8 quarters
Avg Surprise
+147.4%
EPS vs Estimate
Beats / Misses
2/6
Last 12 quarters
Latest EPS
$-0.39
Q4 2025
EPS Surprise History
Q2 24
No data
Q2 24
No data
Q3 24
No data
Q4 24
No data
Q1 25
No data
Q2 25
No data
Q3 25
No data
Q4 25
No data
Beat Estimate
Missed Estimate
Quarterly EPS Details
| Period | Report Date | Estimated EPS | Actual EPS | Surprise | Result |
|---|---|---|---|---|---|
Q1 2026 | Mar 16, 2026 | — | — | — | — |
Q4 2025 | Nov 7, 2025 | — | $-0.39 | — | — |
Q3 2025 | Aug 8, 2025 | — | $-0.41 | — | — |
Q2 2025 | Jun 27, 2025 | — | $-0.45 | — | — |
Q1 2025 | Mar 18, 2025 | — | $-3.39 | — | — |
Q4 2024 | Nov 14, 2024 | — | $-0.57 | — | — |
Q3 2024 | Aug 13, 2024 | — | $-0.35 | — | — |
Q2 2024 | Jun 17, 2024 | — | $-0.50 | — | — |
Q2 2024 | Jun 6, 2024 | — | $-0.68 | — | — |
Q2 2024 | Jun 6, 2024 | — | $-0.65 | — | — |
Q2 2024 | Jun 6, 2024 | — | $-0.66 | — | — |
Q2 2024 | May 16, 2024 | — | $-3.05 | — | — |
Q1 2023 | Mar 27, 2023 | $-0.95 | $20.50 | +2257.9% | ✓ BEAT |
Q4 2022 | Nov 14, 2022 | $-4.50 | $-5.20 | -15.6% | ✗ MISS |
Q3 2022 | Aug 15, 2022 | $-1.20 | $-8.30 | -591.7% | ✗ MISS |
Q2 2022 | May 16, 2022 | $-2.10 | $-10.51 | -400.5% | ✗ MISS |
Q1 2022 | Mar 25, 2022 | $-25.53 | $-22.52 | +11.8% | ✓ BEAT |
Q4 2021 | Nov 19, 2021 | $-24.02 | $-40.54 | -68.8% | ✗ MISS |
Q3 2021 | Aug 12, 2021 | $-22.52 | $-24.02 | -6.7% | ✗ MISS |
Q2 2021 | May 12, 2021 | $-19.52 | $-21.02 | -7.7% | ✗ MISS |
Latest News
Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation achieved its primary endpoint.
📈 PositiveBenzinga•Dec 9, 2025, 02:25 PM
Market-Moving News for December 9th
➖ NeutralBenzinga•Dec 9, 2025, 12:21 PM•Also: ,
Exicure Reports Phase 2 Results For Burixafor Combo In Multiple Myeloma; Achieves 90% Primary Endpoint In HPC Mobilization Ahead Of AHCT
📈 PositiveBenzinga•Dec 8, 2025, 09:41 PM
Exicure shares are trading higher after the company announced results from its completed Phase 2 trial evaluating burixafor combination with propranolol and granulocyte colony-stimulating factor for the mobilization of hematopoietic progenitor cells in patients with multiple myeloma undergoing autologous hematopoietic cell transplantation achieved its primary endpoint.
📈 PositiveBenzinga•Dec 8, 2025, 09:40 PM
Exicure Q3 EPS $(0.39) Up From $(0.57) YoY
📈 PositiveBenzinga•Nov 7, 2025, 09:01 PM
Exicure Says Ongoing Phase 2 Study Of Burixafor In Autologous Stem Cell Transplant For Multiple Myeloma Nears Key Readout
📈 PositiveBenzinga•Oct 6, 2025, 11:04 AM
Frequently Asked Questions about XCUR
What is XCUR's current stock price?
Exicure, Inc. (XCUR) is currently trading at $5.92 per share. The stock has moved -2.79% today.
What is the analyst price target for XCUR?
The average analyst price target for XCUR is $12.00, based on 1 analyst.
What sector is Exicure, Inc. in?
Exicure, Inc. operates in the Healthcare sector, specifically within the Biotechnology industry. The company is traded on the NASDAQ exchange.
What is XCUR's market cap?
Exicure, Inc. has a market capitalization of $0.04 billion, making it a small-cap company.
Does XCUR pay dividends?
No, Exicure, Inc. does not currently pay a dividend to shareholders.
Similar Stocks
Healthcare SectorCLGN
CollPlant Biotechnologies Ltd.
$1.52
Mkt Cap: $0.0B
CVKD
Cadrenal Therapeutics, Inc. Common Stock
$7.11
Mkt Cap: $0.0B
IBIO
iBio, Inc.
$1.98
Mkt Cap: $0.0B
KLTO
Klotho Neurosciences, Inc.
$0.39
Mkt Cap: $0.0B
MTVA
MetaVia Inc.
$8.62
Mkt Cap: $0.0B
NRSN
NeuroSense Therapeutics Ltd.
$0.81
Mkt Cap: $0.0B
NRXS
NeurAxis, Inc.
$3.22
Mkt Cap: $0.0B
RLYB
Rallybio Corporation
$0.79
Mkt Cap: $0.0B
SONN
Sonnet BioTherapeutics Holdings, Inc.
$1.26
Mkt Cap: $0.0B
TAOX
TAO Synergies Inc.
$5.03
Mkt Cap: $0.0B
Explore stocks similar to XCUR for comparison